Article
FDA Issues Warning Letter to Curaleaf for Unsubstantiated Claims About CBD Products
Author(s):
Curaleaf Inc., who sells CBD products marketed to consumers as creams, oil drops, capsules, syrups, and teas, will have 15 days to formulate responses to the letter indicating how the violations will be corrected.
The FDA has issued a warning letter to Curaleaf Inc., for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer disease, opioid withdrawal, pain, and pet anxiety.
According to the warning letter issued to the Massachusetts-based company, product messaging on Curaleaf’s webpages, its online store, and social media websites have made unfounded claims about more than a dozen different CBD products.
Curaleaf, Inc., who sells CBD products marketed to consumers as creams, oil drops, capsules, syrups, and teas, will have 15 days to formulate responses to the letter indicating how the violations will be corrected.
To read the rest of this article, please visit the Total Pharmacy website.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
